Inozyme Pharma’s (INZY) Outperform Rating Reaffirmed at Wedbush
Wedbush reiterated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report published on Tuesday, RTT News reports. Wedbush currently has a $15.00 price target on the stock. Inozyme Pharma Stock Down 0.3 % INZY stock opened at $5.72 on Tuesday. Inozyme Pharma has a twelve month low of $2.59 […]
More Stories
Take Charge of My Heart: Release Date, Trailer, Plot, and More
Are you also hunting for the next Korean romantic-comedy drama? Then your search ends here. Take Charge of My Heart...
Minerva Academy: Release Date, Plot, Cast, Trailer, and More
Netflix’s latest Italian drama Minerva Academy is currently streaming online on the popular streaming network Netflix. Its original title is...
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...